Echo Therapeutics Says It Is in Final Stage of Clinical Research Organization Selection

Echo Therapeutics, Inc.

revealed that it was in the final stage of selecting a Clinical Research Organization (CRO) for the development of a comprehensive regulatory, as well as, clinical strategy for its CGM system. Echo Therapeutics said that following its ongoing diligence process, it would select a full-service CRO with a global reach and a demonstrated track record of successfully designing and managing clinical trials. The company's President and CEO, Scott Hollander, commented, "Identifying the right CRO partner is critical to our success. We are currently in discussions to determine the organization best suited to develop and execute our strategy and to provide consultation as we progress with product development. Based on our progress, I am excited to begin plans for the future clinical trial of our NextGen system." On Wednesday, the stock traded 3.57 percent higher.